Back to News
investment

Stock Market Today, Dec. 16: Tilray Brands Surges 27.5% After Trump Signals Possible Marijuana Reclassification

The Motley Fool
Loading...
2 min read
1 views
0 likes
Stock Market Today, Dec. 16: Tilray Brands Surges 27.5% After Trump Signals Possible Marijuana Reclassification

Summarize this article with:

By Howard Smith – Dec 16, 2025 at 5:00PM ESTNASDAQ: TLRYTilray BrandsMarket Cap$1.3BToday's Changeangle-down(27.54%) $3.01Current Price$13.94Price as of December 16, 2025 at 4:00 PM ETTilray’s jump in a broad cannabis rally shows how shifting U.S. policy signals are jolting traders, today, Dec. 16, 2025.ExpandNASDAQ: TLRYTilray BrandsToday's Change(27.54%) $3.01Current Price$13.94Key Data PointsMarket Cap$1.3BDay's Range$10.50 - $14.5552wk Range$3.51 - $23.20Volume47MAvg Vol9MGross Margin20.17%Tilray Brands (TLRY +27.54%), global medical cannabis producer, closed Tuesday’s session at $13.94, up 27.54%. Trading volume reached 46.8 million shares, about 525% above its three-month average of 8.9 million shares.How the markets moved todayTuesday’s move tracked a sector-wide cannabis rally after President Donald Trump signaled he is considering an executive order to reclassify marijuana. Investors are watching potential U.S. policy changes that could meaningfully impact industry growth. The S&P 500 (^GSPC 0.24%) slipped 0.26% to 6,799, while the Nasdaq Composite (^IXIC +0.23%) added 0.23% to finish at 23,111. Within the sector, cannabis-focused peers Canopy Growth (CGC +10.24%) and Cronos Group (CRON +3.61%) rose 10.24% and 3.61%, underscoring how U.S. rescheduling speculation is lifting the group.What this means for investorsToday's jump has Tilray shares approaching a two-month high. Investors are betting that President Trump's comment that he is "strongly" considering reclassifying marijuana from a Schedule I to a Schedule III drug has investors pouring into cannabis names. An executive order to reclassify the drug to the level of other drugs including Tylenol with Codeine and steroids would increase Tilray's addressable market. It could allow for medical use under federal law for the first time, for example. It's not the first time the potential for reclassification has come up, though. Investors today seem to believe that this is the time for the official change. About the AuthorHoward Smith is a contributing Motley Fool stock market analyst covering technology and industrial stocks. Prior to The Motley Fool, Howard spent nearly 30 years supervising quality and operations in the steel industry, mostly with leading steel company Nucor. He holds a bachelor’s degree in metallurgical engineering from Lafayette College and a master’s degree in environmental engineering from Johns Hopkins University.TMFBuilt2Last

Read Original

Source Information

Source: The Motley Fool